On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Michael S. Gordon

ResearcherPublications, citations & collaboration network

Michael S. Gordon is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Michael S. Gordon have?

ScholarIQindexed works

Michael S. Gordon has 570 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Michael S. Gordon have?

ScholarIQcitation count

Michael S. Gordon has 28,331 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Michael S. Gordon?

ScholarIQh-index

Michael S. Gordon has an h-index of 73 in OpenAlex.

What is the i10-index of Michael S. Gordon?

ScholarIQi10-index

Michael S. Gordon has an i10-index of 235 in OpenAlex.

What is the ORCID of Michael S. Gordon?

ScholarIQorcid

The ORCID for Michael S. Gordon is on the source record.

What is the OpenAlex record for Michael S. Gordon?

ScholarIQopenalex

The OpenAlex for Michael S. Gordon is on the source record.

What are the most-cited papers on Michael S. Gordon?

ScholarIQmost cited works
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith
The Lancet Oncology. 2012559 Citations
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
The Lancet Oncology. 2012545 CitationsOPEN ACCESS
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
Isidore Tepler, Laurence Elias, John W. Smith, Mohamad A. Hussein, Gerald Rosen, A. Y. Chang, Joseph O. Moore, Michael S. Gordon, Bernice Kuca, Kathleen J. Beach, John W. Loewy, Marc B. Garnick, James A. Kaye
PubMed. 1996305 Citations

Related on ScholarIQ

470M+ articles · free account